DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

DEXCOM INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$85.98−0.06 (-0.07%)

Close on Oct 19, 2026

Market cap: $33.54B
P/E (TTM): 34.1
Dividend yield: –

DEXCOM INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	4,662	4,033	3,622	2,910	2,449	1,927	1,476	1,032	719	573	402	259	160	100	76	49	30
Cost of Revenue	1,860	1,595	1,333	1,027	768	647	545	368	226	195	124	83	60	53	40	30	26
Gross Profit	2,802	2,438	2,289	1,883	1,681	1,280	932	664	492	378	278	176	100	47	36	18	3.66
Research & Development	599	552	506	484	517	360	274	200	185	156	138	69	45	38	30	23	14
Selling, General & Admin	1,291	1,286	1,185	1,008	811	618	516	433	349	286	198	128	84	64	51	41	35
Advertising Expenses	224	194	181	161	150	77	33	24	22	12	4.00	–	–	–	–	–	–
Operating Expenses	1,890	1,838	1,691	1,492	1,415	981	789	850	535	442	336	198	129	102	81	64	49
Operating Income	912	600	598	391	266	300	142	-186	-43	-64	-57	-22	-29	-56	-45	-45	-46
Interest Expense	18	19	20	19	19	18	60	23	13	0.70	0.40	0.80	0.90	0.20	0	1.50	8.05
Interest & Investment Income	113	134	135	24	1.70	–	–	–	3.30	0.40	0	0	–	–	0.11	0.10	0.35
Other Non-Operating Income	177	109	113	-0.40	-9.00	16	26	2.40	6.70	-0.70	0	0	–	–	0.00	0.06	0
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	-0.36
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	–	–	–	–	–	–	–
Gain (Loss) on Investments	78	-1.40	1.90	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-7.10	-5.10	-0.70	-2.20	-25	-14	-11	-5.40	-11	–	–	–	–	–	-0.02	-0.10	0
Pretax Income	1,088	709	710	391	257	298	104	-127	-49	-65	-58	-22	-30	-56	-45	-55	–
Income Tax Expense	252	133	169	50	40	-252	3.10	0.60	1.60	0.70	0.10	0.10	0	-1.30	0	0	–
Net Income	836	576	542	341	217	550	101	-127	-50	-66	-58	-22	-30	-55	-45	-55	-54
EPS (Basic)(per share)	2.14	1.46	1.40	0.88	0.56	1.46	0.28	-0.36	-0.15	-0.20	-0.18	-0.08	-0.11	-0.20	-0.17	-0.24	-0.30
EPS (Diluted)(per share)	2.09	1.42	1.30	0.82	0.53	1.33	0.28	-0.36	-0.15	-0.20	-0.18	-0.08	-0.11	-0.20	-0.17	-0.24	-0.30
Shares Outstanding (Basic, Weighted)(shares)	390	394	386	389	387	378	364	353	345	334	319	301	284	275	262	228	–
Shares Outstanding (Diluted, Weighted)(shares)	406	413	426	428	429	420	369	353	345	334	319	301	284	275	262	228	–
EBITDA	1,164	818	784	547	368	367	191	-157	-26	-49	-46	-13	-22	-49	-41	-43	-43

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 62.5%
Operating margin: 22.9%
Net margin: 20.1%
Return on equity, FY2025: 34.5%

Financial strength

Current ratio: 1.73
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 46.9%

Valuation

P/E ratio: 34.1
Price to sales: 6.75
Price to book: 12.79
Dividend yield: –